E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Glucocorticoid induced hyperglycemia |
Glucocorticoid geinduceerde hyperglycemie |
|
E.1.1.1 | Medical condition in easily understood language |
High blood glucose induced by glucocorticoid therapy |
Hoge bloedsuiker als gevolg van glucocorticoïde medicijnen |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to investigate the effectiveness and safety of dapagliflozin for glucose control in patients with exacerbation COPD on high dose glucocorticoids. |
Het doel van de studie is om de effectiviteit en veiligheid van dapagliflozin te onderzoeken, bij patiënten met glucocorticoïd geïnduceerde hyperglycemie tijdens een exacerbatie COPD |
|
E.2.2 | Secondary objectives of the trial |
To investigate the efficacy of dapagliflozin on patient satisfaction, clinical outcomes and various outcomes of glucose control and safety (other than the primary outcomes). |
Onderzoeken van patiënttevredenheid, klinische uitkomsten en verschillende maten van glucose controle en veiligheid (anders dan de primaire uitkomsten). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age ≥ 18 years and ≤100 years at baseline - Informed consent - Hospitalization due to AECOPD - Treatment with ≥30mg prednisone daily or equivalent dose of glucocorticoid for AECOPD - An expected duration of glucocorticoid treatment of 3-14 days at study entry - Known type 2 diabetes or glucose ≥ 10 mmol/l at admission
|
|
E.4 | Principal exclusion criteria |
- Maintenance treatment with systemic glucocorticoids or glucocorticoid treatment started ≥7 days before study entry - Need for ICU admission - Chronic kidney disease stage G3 (glomerular filtration rate <60ml/minute) - Recurrent genital or urinary tract infection - Current use of any SGLT-2 inhibiting agent - Suspected volume depletion - Congestive heart failure functional classification NYHA class IV/IV or instable heart failure - Acute stroke within 2 months before inclusion. - Recent cardiovascular event: acute coronary syndrome, hospitalisation for unstable angina or coronary revascularisation within 2 months before inclusion - Suspected liver disease, confirmed by AST/ALT > 3x ULN or bilirubin >2.0mg/dl (34.2 μmol/l) or serologically proven infection with hepatitis B or hepatitis C - Pregnancy or breast feeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effectiveness: The difference in mean percentage time spent within glucose target range on 2nd till 7th day of treatment, between the dapagliflozin group and the control group as measured by subcutaneous continuous glucose monitor. Target range is defined as fasting glucose 4-7.8 mmol/l and random glucose 4-10 mmol/l according to ADA guidelines for non-critically ill inpatients (20). Safety: Incidence rate of hypoglycaemic events per patient-day. A hypoglycaemic event is defined according to Whipple´s criteria (i.e. symptoms known or likely to be caused by hypoglycaemia, interstitial glucose ≤ 3.9 mmol/l continuing until the interstitial glucose is >3.9 mmol/l, relief of symptoms when glucose is raised to normal).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
2nd till 7th day of treatment |
|
E.5.2 | Secondary end point(s) |
1. Patient satisfaction measured by Diabetes Treatment Satisfaction Questionnaire for inpatients (DTSP-IP) (21) specifically directed at glucose lowering treatment. 2. Clinical outcomes: duration of hospitalisation, need for intensification of treatment for AECOPD, change in body weight and blood pressure during investigational treatment. 3. Other parameters of glucose control: - Glucose variability by mean amplitude of glycaemic excursion (MAGE) - Total daily dose of insulin - Mean daily glucose concentration - Mean percentage time spent within glucose target range from start till end of treatment 4. Safety: incidence rate of asymptomatic hypoglycaemia, incidence of genital infections and urinary tract infections, incidence of other adverse events.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During complete follow-up |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |